Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Kiniksa Pharmaceuticals International's Current Deferred Revenue history spans 3 years, with the latest figure at $31.8 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 10261.89% year-over-year to $31.8 million; the TTM value through Dec 2024 reached $31.8 million, up 10261.89%, while the annual FY2024 figure was $31.8 million, 10261.89% up from the prior year.
  • Current Deferred Revenue reached $31.8 million in Q4 2024 per KNSA's latest filing, up from $12000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $31.8 million in Q4 2024 to a low of $12000.0 in Q2 2024.
  • Average Current Deferred Revenue over 3 years is $9.4 million, with a median of $4.7 million recorded in 2023.
  • The largest YoY upside for Current Deferred Revenue was 10261.89% in 2024 against a maximum downside of 99.74% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $12.0 million in 2022, then crashed by 97.44% to $307000.0 in 2023, then soared by 10261.89% to $31.8 million in 2024.
  • Per Business Quant, the three most recent readings for KNSA's Current Deferred Revenue are $31.8 million (Q4 2024), $12000.0 (Q2 2024), and $156000.0 (Q1 2024).